Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients
Recruiting now · Not applicable
Conditions studied: Symbiotic, Uremic Toxins, Gut -Microbiota, Gut Permeability, Hemodialysis
In brief
Chronic kidney disease (CKD) patients undergoing maintenance hemodialysis experience profound alterations in their gut microbiota, leading to dysbiosis and increased gut permeability. This disruption facilitates the translocation of endotoxins and gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate into the systemic circulation, contributing to heightened systemic inflammation, cardiovascular disease risk, and accelerated CKD progression. Synbiotic supplementation, particularly multispecies formulations, has emerged as a promising therapeutic strategy to restore gut microbial balance, enhance intestinal barrier integrity, and reduce the systemic burden of deleterious microbial metabolites. These probiotics potentially improve clinical outcomes by modulating inflammatory pathways and decreasing circulating levels of uremic toxins. Despite these insights, few clinical trials have comprehensively assessed the effects of multispecies synbiotic on fecal microbiome composition, gut permeability and uremic toxin profiles in hemodialysis patients. This pilot study aims to fill this gap by evaluating the modulatory effects of a 12-week multispecies synbiotic intervention.
Key facts
- Study ID
- NCT07461233
- Run by
- Tungs' Taichung Metroharbour Hospital
- People needed
- 30
- Starts
- 2026-05-04
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-06-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months
You may not qualify if…
- Use of probiotic supplements within the last month;
- Hospitalization within the past month for acute infections or CKD-related complications;
- History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);
- Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;
- Use of antibiotics or immunosuppressive therapy within the preceding three months.
Where it is running
- Tungs' Taichung Metroharbour Hospital — Taichung, Wuqi District, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.